SLE
MCID: LPS004
MIFTS: 62

Lupus Erythematosus (SLE)

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Nephrological diseases, Rare diseases, Skin diseases

Aliases & Classifications for Lupus Erythematosus

MalaCards integrated aliases for Lupus Erythematosus:

Name: Lupus Erythematosus 12 75 53 55 15 72 33
Lupus 12 53 15
Subacute Cutaneous Lupus 53 72
Disseminated Lupus Erythematosus 53
Lupus Erythematosus, Systemic 72
Systemic Lupus Erythematosus 53
Lupus Erythematosus, Discoid 72
Lupus Vulgaris 72
Discoid Lupus 53
Sle 53

Classifications:



External Ids:

Disease Ontology 12 DOID:8857
ICD9CM 35 695.4
NCIt 50 C27153
ICD10 33 L93 L93.0
UMLS 72 C0024131 C0024138 C0024141 more

Summaries for Lupus Erythematosus

NIH Rare Diseases : 53 Lupus is an autoimmune disease that can affect almost every organ in the body. Symptoms of lupus can range from very mild to life-threatening. There are three main types of lupus; systemic lupus erythematosus, discoid lupus, and drug-induced lupus. Symptoms may include pain or swelling in joints, muscle pain, fever, red rashes, most often on the face (also called the "butterfly rash"), hair loss, chest pain, sensitivity to the sun, swelling in legs or around the eyes, and feeling tired. Genetics is thought to play a role in the development of lupus along with other lifestyle and environmental factors. Studies suggest that a number of different genes may be involved in determining a person's likelihood of developing the disease, which tissues and organs are affected, and the severity of disease. Lupus is more common in young women. The treatment of lupus depends on the severity of the condition and what parts of the body are affected. Treatment may include acetaminophen, ibuprofen, antimalarial drugs, anti-inflammatory steroids, immunosuppressive drugs, and other such as BLyS-specific inhibitors (Belimumab).

MalaCards based summary : Lupus Erythematosus, also known as lupus, is related to systemic lupus erythematosus 16 and neonatal lupus erythematosus, and has symptoms including rashes, seizures and pruritus. An important gene associated with Lupus Erythematosus is TLR5 (Toll Like Receptor 5), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Prednisolone phosphate and Methylprednisolone hemisuccinate have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and skin, and related phenotypes are no effect and hematopoietic system

Disease Ontology : 12 An autoimmune hypersensitivity disease that is characterized by a constellation of findings that include elevated antibodies to nuclear antigens, antiphospholipids, low complement levels, ulcers, non-scarring alopecia, renal or neurologic damage, and low white blood cell and platelet counts, has symptom rashes, fatigue, arthritis, hair loss, seizures, and symptoms related to affected organs, and has material basis in autoimmune disorder.

Wikipedia : 75 Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes... more...

Related Diseases for Lupus Erythematosus

Diseases in the Lupus Erythematosus family:

Systemic Lupus Erythematosus Systemic Lupus Erythematosus 15
Systemic Lupus Erythematosus 1 Systemic Lupus Erythematosus 2
Systemic Lupus Erythematosus 3 Systemic Lupus Erythematosus 4
Systemic Lupus Erythematosus 5 Systemic Lupus Erythematosus 6
Systemic Lupus Erythematosus 7 Systemic Lupus Erythematosus 8
Systemic Lupus Erythematosus 9 Systemic Lupus Erythematosus 10
Systemic Lupus Erythematosus 11 Systemic Lupus Erythematosus 12
Systemic Lupus Erythematosus 13 Systemic Lupus Erythematosus 14
Systemic Lupus Erythematosus 16

Diseases related to Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2330)
# Related Disease Score Top Affiliating Genes
1 systemic lupus erythematosus 16 35.3 DNASE1L3 DNASE1 C4A C1QA
2 neonatal lupus erythematosus 35.2 TRIM21 C4A
3 pediatric systemic lupus erythematosus 35.0 STAT4 C4B C4A
4 vitiligo-associated multiple autoimmune disease susceptibility 1 34.5 PTPN22 PDCD1 CTLA4
5 c1q deficiency 33.8 C1QC C1QB C1QA
6 sjogren syndrome 33.5 TRIM21 TNFSF4 SSB
7 autoimmune disease 32.9 STAT4 PTPN22 PDCD1 IRF5 CTLA4
8 systemic lupus erythematosus 32.6 TRIM21 TNFSF4 TLR5 STAT4 SSB SNRPB
9 glomerulonephritis 32.3 C4B C4A C1QC C1QB
10 primary biliary cholangitis 31.4 IRF5 CTLA4
11 multifocal motor neuropathy 30.6 PTPN22 FCGR2B BANK1
12 cutaneous lupus erythematosus 13.0
13 lupus erythematosus tumidus 13.0
14 discoid lupus erythematosus 13.0
15 drug-induced lupus erythematosus 12.9
16 subacute cutaneous lupus erythematosus 12.9
17 lupus erythematosus panniculitis 12.9
18 systemic lupus erythematosus 1 12.9
19 systemic lupus erythematosus 2 12.8
20 systemic lupus erythematosus 10 12.8
21 systemic lupus erythematosus 9 12.8
22 systemic lupus erythematosus 6 12.8
23 systemic lupus erythematosus 11 12.8
24 chronic cutaneous lupus erythematosus 12.6
25 systemic lupus erythematosus with hemolytic anemia 1 12.6
26 systemic lupus erythematosus 3 12.6
27 neonatal systemic lupus erythematosus 12.6
28 systemic lupus erythematosus 4 12.6
29 systemic lupus erythematosus 7 12.6
30 systemic lupus erythematosus 15 12.6
31 systemic lupus erythematosus 8 12.6
32 systemic lupus erythematosus 13 12.6
33 systemic lupus erythematosus 5 12.6
34 systemic lupus erythematosus 12 12.6
35 systemic lupus erythematosus 14 12.6
36 systemic lupus erythematosus with nephritis 1 12.6
37 systemic lupus erythematosus with nephritis 2 12.6
38 systemic lupus erythematosus with nephritis 3 12.6
39 rare cutaneous lupus erythematosus 12.5
40 chilblain lupus 1 12.5
41 hypertrophic or verrucous lupus erythematosus 12.5
42 obsolete: bullous systemic lupus erythematosus 12.5
43 discoid lupus erythematosus of eyelid 12.3
44 obsolete: acute cutaneous lupus erythematosus 12.3
45 obsolete: maculopapular lupus rash 12.0
46 mixed connective tissue disease 12.0
47 antiphospholipid syndrome 11.9
48 complement component 2 deficiency 11.8
49 hypogonadotropic hypogonadism 11.8
50 aicardi-goutieres syndrome 11.8

Graphical network of the top 20 diseases related to Lupus Erythematosus:



Diseases related to Lupus Erythematosus

Symptoms & Phenotypes for Lupus Erythematosus

Symptoms:

12
  • rashes

UMLS symptoms related to Lupus Erythematosus:


seizures, pruritus, exanthema, heliotrope rash, lupus-like rash

GenomeRNAi Phenotypes related to Lupus Erythematosus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 BANK1 C1QA C1QB C1QC C4A C4B

MGI Mouse Phenotypes related to Lupus Erythematosus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.17 BANK1 C4B CR2 CTLA4 DNASE1 FCGR2B
2 homeostasis/metabolism MP:0005376 10.07 C1QA C4B CR2 CTLA4 DNASE1 FCGR2B
3 immune system MP:0005387 10.03 BANK1 C1QA C4B CR2 CTLA4 DNASE1
4 mortality/aging MP:0010768 9.73 C1QA C4B CR2 CTLA4 DNASE1 FCGR2B
5 renal/urinary system MP:0005367 9.28 C1QA C4B CR2 DNASE1 FCGR2B PDCD1

Drugs & Therapeutics for Lupus Erythematosus

Drugs for Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 487)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
2
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Mycophenolic acid Approved Phase 4 24280-93-1 446541
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
7
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
9
Lenalidomide Approved Phase 4 191732-72-6 216326
10
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
11
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
12
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
13
Vincristine Approved, Investigational Phase 4 57-22-7, 2068-78-2 5978
14
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
15
Linaclotide Approved Phase 4 851199-59-2 65351
16
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
17
tannic acid Approved Phase 4 1401-55-4
18
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
19
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
20
Sulfamethoxazole Approved Phase 4 723-46-6 5329
21
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
22
Lifitegrast Approved Phase 4 1025967-78-5
23
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
24
Artesunate Approved, Investigational Phase 4 88495-63-0 5464098 6917864
25
Dalteparin Approved Phase 4 9005-49-6
26
Metformin Approved Phase 4 657-24-9 4091 14219
27
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
28
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
29
Adenosine Approved, Investigational Phase 4 58-61-7 60961
30
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
31
Simvastatin Approved Phase 4 79902-63-9 54454
32
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
33
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
34
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
35 Gastrointestinal Agents Phase 4
36 Dermatologic Agents Phase 4
37 Anti-Asthmatic Agents Phase 4
38 Antiemetics Phase 4
39 Neuroprotective Agents Phase 4
40 Prednisolone acetate Phase 4
41 Methylprednisolone Acetate Phase 4
42 Protective Agents Phase 4
43 Autonomic Agents Phase 4
44 Angiotensin-Converting Enzyme Inhibitors Phase 4
45 Rosuvastatin Calcium Phase 4 147098-20-2
46 Antitubercular Agents Phase 4
47 Antibiotics, Antitubercular Phase 4
48 Chloroquine diphosphate Phase 4 50-63-5
49 Antifungal Agents Phase 4
50 Hydroxycholecalciferols Phase 4

Interventional clinical trials:

(show top 50) (show all 1024)
# Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Endothelial Dysfunction in Systemic Lupus Erythematosus: Its Contribution to Abnormalities in Coronary Perfusion. Unknown status NCT00188188 Phase 4 quinipril
3 A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease Unknown status NCT01753401 Phase 4 Acthar;Placebo for Acthar
4 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
5 Low Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled Trial Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
6 A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE) Completed NCT01632241 Phase 4 Standard therapy
7 A Prospective, Randomised, Double-blind, Placebo-controlled Trial Evaluating the Effects of Mycophenolate Mofetil on 'Surrogate Markers' for Atherosclerosis in Female Patients With SLE. Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
8 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
9 A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
10 Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus, a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01322308 Phase 4 pioglitazone;placebo
11 Study of the Reduction of Systemic Lupus Erythematosus Flares Through Adaptation of the Dosage of Hydroxychloroquine to Its Whole-blood Concentration. National Multicenter Randomized Prospective Study Completed NCT00413361 Phase 4 versus hydroxychloroquine
12 A Single-site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection)an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) Completed NCT01769937 Phase 4 H.P. Acthar Gel
13 Lupus Atherosclerosis Prevention Study Completed NCT00120887 Phase 4 Atorvastatin
14 A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Omega-3-polyunsaturated Fatty Acids in Subjects With SLE. Completed NCT00828178 Phase 4 Omega-3
15 Effect Of Hormone Replacement Therapy On Disease Activity, Menopausal Symptoms And Bone Mineral Density In Peri/Postmenopausal Women With Systemic Lupus Erythematosus.Randomized Clinical Trial Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
16 Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus (SLE): a Controlled Study Completed NCT00911521 Phase 4 human papillomavirus vaccination (Gardasil)
17 Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus-Prevalence,Risk Factors and Treatment Completed NCT00668330 Phase 4 Ibandronate+alfacalcidol+calcium;placebo ibandronate+alfacalcidol+calcium
18 Randomized Controlled Trial to Evaluate the Efficacy of Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Induction and Maintenance of Remission of the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
19 Immunogenicity and Safety of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Completed NCT03540823 Phase 4
20 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
21 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
22 Evaluation of Vaccination Against Influenza (Seasonal and H1N1) in Patients Presenting Systemic or Autoimmune Diseases Treated or Not With Steroids, and/or Immunosuppressant, and/or Biotherapy: an Open, Prospective Trial (MAIVAX) Completed NCT01065285 Phase 4
23 Comparison of Intravenous Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Proliferative Lupus Nephritis Completed NCT02645565 Phase 4 Cyclophosphamide;Azathioprine;Methylprednisolone
24 Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease Completed NCT02351752 Phase 4 Hydroxychloroquine Sulfate
25 Possible Role of Chloroquine in Conjunction to Prednisone to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial Completed NCT02463331 Phase 4 Chloroquine diphosphate;prednisone;azathioprine
26 DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL WITH CHLOROQUINE VERSUS PLACEBO FOR MAINTENANCE OF REMISSION OF AUTOIMMUNE HEPATITIS Completed NCT01980745 Phase 4 Chloroquine diphosphate 250mg;Placebo
27 Estimation of Interleukin-21 Levels in Gingival Crevicular Fluid in Patients With Periodontal Health and Disease Following Non-surgical Periodontal Therapy: A Clinico-biochemical Study Completed NCT02861937 Phase 4
28 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
29 Open Label Study of Hydroxychloroquine for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
30 Effects of Atorvastatin on Disease Activity and HDL Cholesterol Anti-inflammatory Properties in Patients With Rheumatoid Arthritis Completed NCT00356473 Phase 4 Atorvastatin
31 Management of Pain in Oral Lichen Planus Patients: A Comparative Pilot Study Completed NCT03572959 Phase 4 0.1 % topical triamcinolone acetonide
32 Low-dose Combination of Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis: a 12-month Prospective Study Completed NCT01203709 Phase 4 low dose combination of MMF and Tac
33 To Compare the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Completed NCT00371319 Phase 4 tacrolimus;mycophenolate mofetil
34 Phase II Study To Evaluate The Safety And Efficacy Of Lenalidomide For The Treatment Of Refractory Cutaneous Lupus Completed NCT01408199 Phase 4 Lenalidomide
35 Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® Completed NCT02437786 Phase 4 GRAZAX
36 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
37 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
38 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
39 A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy Completed NCT00498368 Phase 4 Intravenous Rituximab;ACE/ARB
40 A Prospective, Randomized, Open Label, Case-Controlled Study on the Efficacy of Mycophenolate Mofetil for IgA Nephropathy Patients With Heavy Proteinuria Despite Angiotensin Blockade Completed NCT00863252 Phase 4 mycophenolate mofetil;angiotensin blockade
41 A Phase IV, Open Label Study to Evaluate the Safety and Efficacy of Intramuscular (IM) Alefacept (Amevive) 15mg/wk in Subjects 18 Years and Older With Moderate to Severe Atopic Dermatitis Completed NCT00832585 Phase 4 Alefacept
42 Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study Completed NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
43 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
44 Pilot Open-Label Clinical Trial to Test Efficacy and Safety of Combination of Clobex® Spray With Excimer Laser Therapy [Photomedex XTRAC ® Velocity] in the Treatment of Generalized Plaque Psoriasis Followed by Maintenance With Topical Vectical® Ointment Completed NCT01012713 Phase 4 Clobex Spray;Vectical Ointment
45 Prophylactic Trimethoprim-Sulfamethoxazole for the Prevention of Serious Infections in Patients With Systemic Lupus Erythematosus: a Randomized Placebo Controlled Trial Recruiting NCT03042260 Phase 4 Trimethoprim-Sulfamethoxazole;Placebo Oral Tablet
46 A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids Recruiting NCT02953821 Phase 4 Repository corticotropin injection;Placebo gel
47 Efficacy, Safety, and Steroid Sparing Effect of Acthar in Patients With Hematologic Manifestations of Systemic Lupus Erythematosus Recruiting NCT02779153 Phase 4 Acthar low dose (40 U);Acthar high dose (80 U)
48 Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects Recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
49 Open-label Prospective Randomized Study to Determine the Efficacy and Safety of Two Dosing Regimens of ACTHar in the Treatment of Proliferative Lupus Nephritis. Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
50 Efficacy and Infectious Complications of Induction Therapy With Low-dose Versus High-dose Intravenous Cyclophosphamide for Proliferative Lupus Nephritis in Children Recruiting NCT01861561 Phase 4 Low-dose intravenous cyclophosphamide;High-dose intravenous cyclophosphamide

Search NIH Clinical Center for Lupus Erythematosus

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Azathioprine
Betamethasone
Chloroquine
Chloroquine hydrochloride
chloroquine phosphate
Cyclosporine
Hydroxychloroquine
Hydroxychloroquine Sulfate
prasterone
Tetracosactide
Thalidomide
Triamcinolone
Triamcinolone Acetonide
TRIAMCINOLONE ACETONIDE PWDR
triamcinolone diacetate
triamcinolone hexacetonide

Genetic Tests for Lupus Erythematosus

Anatomical Context for Lupus Erythematosus

MalaCards organs/tissues related to Lupus Erythematosus:

41
T Cells, B Cells, Skin, Testes, Kidney, Bone, Heart

Publications for Lupus Erythematosus

Articles related to Lupus Erythematosus:

(show top 50) (show all 39245)
# Title Authors PMID Year
1
Vaccination, atherosclerosis and systemic lupus erythematosus. 9 38
19880570 2009
2
[Association of interleukin-18 gene polymorphism with genetic susceptibility to systematic lupus erythematosus in Guangxi Zhuang population]. 9 38
18683145 2008
3
Clinical manifestations and vascular events in patients with lupus erythematosus anticardiolipin antibodies and raynaud's phenomenon. 9 38
17550096 2006
4
Vasculopathy and renal injury in lupus erythematosus: does shedding of the endothelial protein C receptor play a role? 9 38
15954934 2005
5
Sudden sensorineural hearing loss in lupus erythematosus associated with antiphospholipid syndrome: case report and review. 9 38
15825571 2005
6
The concomitant presence of lupus anticoagulant, anticardiolipin and anti-beta2-glycoprotein i antibodies could be associated with acquired activated protein c resistance in non-systemic lupus erythematosus patients. 9 38
12716380 2003
7
Catalytic heterogenity of polyclonal RNA-hydrolyzing IgM from sera of patients with lupus erythematosus. 9 38
11208354 2000
8
Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. 9 38
10599336 1999
9
Mucocutaneous disease in Arabs with systemic lupus erythematosus: clinical expression and relevance to autoantibodies. 9 38
9863895 1998
10
Autoantibody response to the Ro/La particle may predict outcome in neonatal lupus erythematosus. 9 38
7774062 1995
11
Renal transplantation in anticardiolipin antibody-positive lupus erythematosus patients. 9 38
8311089 1994
12
Prevalence of anticardiolipin antibodies in subacute cutaneous lupus erythematosus. 9 38
1301991 1992
13
Neonatal lupus erythematosus syndrome: analysis of C4 allotypes and C4 genes in 18 families. 9 38
1545698 1992
14
[Anticardiolipin antibodies in cutaneous lupus erythematosus. Incidence and importance as a marker of vascular symptoms]. 9 38
1577600 1992
15
Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies. 9 38
2317112 1990
16
Glomerular expression of matrix metalloproteinases in systemic lupus erythematosus in association with activity index and renal function. 38
30973283 2019
17
Spontaneous intracranial hypotension in a patient with systemic lupus erythematosus. 38
31428214 2019
18
Traumatic lingual haematoma: Another unusual cause of upper airway obstruction in systemic lupus erythematosus. 38
31372486 2019
19
Cutaneous manifestations of pediatric lupus. 38
31085940 2019
20
Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome. 38
31376888 2019
21
Pancreatic panniculitis in active systemic lupus erythematosus. 38
31081550 2019
22
Update on the treatment and outcome of systemic lupus erythematous in children. 38
31107290 2019
23
Intracerebroventricular administration of lupus serum induces microglia activation and leukocyte adhesion in the cerebromicrovasculature of mice. 38
31207553 2019
24
Adverse cutaneous drug reactions with antimalarials in cutaneous lupus and dermatomyositis: A retrospective cohort study. 38
31085265 2019
25
Characteristics and risk factors of an emergency department visit in patients with systemic lupus erythematosus. 38
31309295 2019
26
Progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus: Clues to early diagnosis. 38
31278051 2019
27
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. 38
31383717 2019
28
Current mechanistic insights into the role of infection in systemic lupus erythematosus. 38
31226637 2019
29
Trace Elements Associated with Systemic Lupus Erythematosus and Insulin Resistance. 38
30600500 2019
30
Lipidomics in autoimmune diseases with main focus on systemic lupus erythematosus. 38
31207360 2019
31
Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. 38
31217170 2019
32
'-Omics' shed light on B cells in lupus. 38
31285628 2019
33
The State of Lupus Clinical Trials: Minority Participation Needed. 38
31426523 2019
34
Update on the pathogenesis of central nervous system lupus. 38
31415031 2019
35
Blood-Brain Barrier Permeability in Patients with Systemic Lupus Erythematosus. 38
31345948 2019
36
Burden of comorbidities in South Africans with systemic lupus erythematosus. 38
30963335 2019
37
Altered Olfactory Function in Patients with Systemic Lupus Erythematosus. 38
31395849 2019
38
Cerebral blood flow abnormalities in neuropsychiatric systemic lupus erythematosus. 38
31315530 2019
39
Combined brain/heart magnetic resonance imaging in systemic lupus erythematosus. 38
31368877 2019
40
Predicting flares in patients with stable systemic lupus erythematosus. 38
30660381 2019
41
Seborrheic area involvement in patients with systemic lupus erythematosus. 38
30849193 2019
42
MDSCs: friend or foe in systemic lupus erythematosus. 38
31431693 2019
43
Mental disorders in systemic lupus erythematosus: a cohort study. 38
31432225 2019
44
Disseminated discoid lupus erythematosus mimicking Degos disease. 38
31429927 2019
45
Metastatic prostate cancer presenting as subacute cutaneous lupus erythematosus. 38
31407804 2019
46
Lupus: the new epidemic. 38
31299878 2019
47
Patient-Reported Outcomes Predict Mortality in Lupus. 38
30144293 2019
48
Malignancies in systemic lupus erythematosus: an update. 38
31403485 2019
49
[State of the art: systemic lupus erythematosus]. 38
31028474 2019
50
Infectious processes and systemic lupus erythematosus. 38
31386190 2019

Variations for Lupus Erythematosus

Expression for Lupus Erythematosus

Search GEO for disease gene expression data for Lupus Erythematosus.

Pathways for Lupus Erythematosus

Pathways related to Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 TRIM21 TNFSF4 TLR5 PTPN22 PDCD1 IRF5
2
Show member pathways
12.83 TLR5 IRF5 C1QC C1QB C1QA
3 12.4 TNFSF4 STAT4 PTPN22 PDCD1 IRF5 CTLA4
4
Show member pathways
11.93 C4B C4A C1QC C1QB C1QA
5 11.88 CR2 C4B C4A C1QC C1QB C1QA
6
Show member pathways
11.76 CR2 C4B C4A C1QC C1QB C1QA
7 11.6 C4B C4A C1QC C1QB C1QA
8
Show member pathways
11.46 CR2 C4B C4A C1QC C1QB C1QA
9 11.38 TNFSF4 PDCD1 CR2
10 11.18 C1QC C1QB C1QA
11 11.08 FCGR2B C4B C4A C1QC C1QB C1QA

GO Terms for Lupus Erythematosus

Cellular components related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen trimer GO:0005581 9.33 C1QC C1QB C1QA
2 blood microparticle GO:0072562 9.26 C4B C4A C1QC C1QB
3 complement component C1 complex GO:0005602 8.62 C1QB C1QA

Biological processes related to Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.97 TNFSF4 FCGR2B CTLA4 CR2 C1QC
2 immune system process GO:0002376 9.87 TLR5 PTPN22 IRF5 CTLA4 CR2 C4B
3 inflammatory response GO:0006954 9.83 TNFSF4 TLR5 FCGR2B C4B C4A
4 complement activation GO:0006956 9.65 C4B C4A C1QC C1QB C1QA
5 complement activation, classical pathway GO:0006958 9.63 CR2 C4B C4A C1QC C1QB C1QA
6 positive regulation of interleukin-12 production GO:0032735 9.61 TNFSF4 IRF5
7 negative regulation of B cell proliferation GO:0030889 9.6 FCGR2B CTLA4
8 regulation of innate immune response GO:0045088 9.59 PTPN22 FCGR2B
9 negative regulation of immune response GO:0050777 9.58 FCGR2B CTLA4
10 histone mRNA metabolic process GO:0008334 9.58 SSB SNRPB
11 DNA catabolic process, endonucleolytic GO:0000737 9.56 DNASE1L3 DNASE1
12 negative regulation of interleukin-6 secretion GO:1900165 9.55 PTPN22 BANK1
13 regulation of adaptive immune response GO:0002819 9.54 TNFSF4 FCGR2B
14 negative regulation of B cell activation GO:0050869 9.52 FCGR2B BANK1
15 positive regulation of apoptotic cell clearance GO:2000427 9.51 C4B C4A
16 neutrophil activation involved in immune response GO:0002283 9.49 DNASE1L3 DNASE1
17 negative regulation of regulatory T cell differentiation GO:0045590 9.48 TNFSF4 CTLA4
18 DNA catabolic process GO:0006308 9.46 DNASE1L3 DNASE1
19 regulation of complement activation GO:0030449 9.43 CR2 C4B C4A C1QC C1QB C1QA
20 regulation of acute inflammatory response GO:0002673 9.4 DNASE1L3 DNASE1
21 regulation of neutrophil mediated cytotoxicity GO:0070948 9.37 DNASE1L3 DNASE1
22 innate immune response GO:0045087 9.28 TRIM21 TLR5 IRF5 CR2 C4B C4A

Molecular functions related to Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase binding GO:1990782 9.26 PTPN22 BANK1
2 deoxyribonuclease activity GO:0004536 9.16 DNASE1L3 DNASE1
3 deoxyribonuclease I activity GO:0004530 8.96 DNASE1L3 DNASE1
4 complement binding GO:0001848 8.62 CR2 C4B

Sources for Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....